MV Capital Management Inc. Decreases Stock Holdings in Danaher Corporation $DHR

MV Capital Management Inc. decreased its stake in shares of Danaher Corporation (NYSE:DHR) by 45.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 307 shares of the conglomerate’s stock after selling 252 shares during the period. MV Capital Management Inc.’s holdings in Danaher were worth $61,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. ABN Amro Investment Solutions purchased a new stake in Danaher during the 2nd quarter valued at $92,327,000. Candriam S.C.A. boosted its stake in shares of Danaher by 12.3% in the 2nd quarter. Candriam S.C.A. now owns 451,933 shares of the conglomerate’s stock worth $89,279,000 after buying an additional 49,409 shares during the last quarter. Impax Asset Management Group plc grew its holdings in shares of Danaher by 37.3% in the second quarter. Impax Asset Management Group plc now owns 521,998 shares of the conglomerate’s stock worth $102,288,000 after acquiring an additional 141,824 shares during the period. Calamos Advisors LLC increased its position in Danaher by 27.6% during the second quarter. Calamos Advisors LLC now owns 259,681 shares of the conglomerate’s stock valued at $51,297,000 after acquiring an additional 56,208 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey increased its position in Danaher by 3.2% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 96,902 shares of the conglomerate’s stock valued at $19,142,000 after acquiring an additional 2,961 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on DHR. Evercore ISI raised their target price on Danaher from $226.00 to $245.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. Rothschild Redb cut shares of Danaher from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 8th. Wall Street Zen downgraded shares of Danaher from a “buy” rating to a “hold” rating in a report on Monday. Barclays upped their target price on shares of Danaher from $225.00 to $250.00 and gave the company an “overweight” rating in a report on Wednesday, October 22nd. Finally, Deutsche Bank Aktiengesellschaft increased their price target on shares of Danaher from $235.00 to $250.00 and gave the stock a “buy” rating in a research report on Wednesday, October 22nd. Eighteen investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and a consensus target price of $243.39.

Danaher Price Performance

NYSE DHR opened at $221.50 on Friday. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.33. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $258.23. The stock has a market cap of $156.46 billion, a price-to-earnings ratio of 45.67, a PEG ratio of 3.28 and a beta of 0.81. The company’s 50 day moving average is $205.21 and its two-hundred day moving average is $200.91.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The firm had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $6 billion. During the same period in the prior year, the company posted $1.71 earnings per share. The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. As a group, research analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Friday, September 26th were issued a dividend of $0.32 per share. The ex-dividend date of this dividend was Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. Danaher’s dividend payout ratio (DPR) is currently 26.39%.

Insider Activity

In other news, Director Teri List sold 2,778 shares of the company’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the transaction, the director owned 20,751 shares of the company’s stock, valued at $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Brian W. Ellis sold 21,776 shares of the stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total value of $4,773,952.48. Following the sale, the senior vice president owned 14,553 shares of the company’s stock, valued at $3,190,454.19. This represents a 59.94% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 29,728 shares of company stock worth $6,448,990 over the last ninety days. Corporate insiders own 11.20% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.